Nivolumab extends survival for patients with the most common lung cancer

Bookmark and Share
Published: 29 May 2015
Views: 4523
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Dr Luis Paz-Ares talks to ecancertv at ASCO 2015 about findings from a randomised phase III study that indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC).

Read the news article for more or watch the press conference video for more.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.